利用 CRISPR/Cas9 工程改造 T 细胞用于癌症治疗。

Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.

机构信息

State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.

University of Chinese Academy of Sciences, Beijing, China.

出版信息

Methods Mol Biol. 2020;2115:419-433. doi: 10.1007/978-1-0716-0290-4_23.

DOI:10.1007/978-1-0716-0290-4_23

PMID:32006414

Abstract

Recent advances in the development of gene editing technologies, especially the CRISPR/Cas 9 system, have substantially enhanced our ability to make precise and efficient changes in the genomes of various cells. In particular, the genetic engineering of T cells holds huge potential to improve the efficacy and safety of T cells-based cancer therapy. Due to its ease of use and high efficiency, CRISPR/Cas9 enables efficient gene knockout, site-specific knock-in, and genome-wide screen in T cells. Here we review the current progress of applying gene editing to T-cell therapy, focusing on the technical aspects of the CRISPR/Cas9 platform. We also discuss the challenges and future prospects.

摘要

近年来，基因编辑技术的发展取得了重大进展，尤其是 CRISPR/Cas9 系统，极大地提高了我们在各种细胞基因组中进行精确和高效修饰的能力。特别是，T 细胞的基因工程具有极大的潜力来提高基于 T 细胞的癌症治疗的疗效和安全性。由于其易用性和高效率，CRISPR/Cas9 能够在 T 细胞中实现高效的基因敲除、定点敲入和全基因组筛选。在这里，我们综述了将基因编辑应用于 T 细胞治疗的最新进展，重点介绍了 CRISPR/Cas9 平台的技术方面。我们还讨论了挑战和未来前景。